SUSTAINED EFFICACY OF BIMEKIZUMAB TREATMENT ASSESSED USING COMPOSITE DISEASE ACTIVITY MEASURES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROMTHE PHASE 3 BE COMPLETE STUDY AND ITS OPEN LABEL EXTENSION UP TO 1 YEAR

被引：0

作者：

Coates, L. ^{[1
,2
]}

Landewe, R. B. M. ^{[3
]}

Mcinnes, I. ^{[4
]}

Ritchlin, C. T. ^{[5
]}

Gottlieb, A. B. ^{[6
]}

Orbai, A. M. ^{[7
]}

Warren, R. B. ^{[8
]}

Ink, B. ^{[9
]}

Bajracharya, R.

Coarse, J. ^{[10
]}

Merola, J. F. ^{[11
]}

机构：

[1] Univ Oxford, Oxford Univ Hosp NHS Trust, Nuffield Dept Orthopaed, Rheumatol & Musculoskeletal Dis, Oxford, England

[2] Oxford Biomed Res Ctr, Oxford, England

[3] Amsterdam & Zuyderland MC, Amsterdam Rheumatol Clin Immunol Ctr, Heerlen, Netherlands

[4] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow, Scotland

[5] Univ Rochester, Allergy Immunol Rheumatol Div, Med Sch, Rochester, NY USA

[6] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA

[7] Johns Hopkins Univ, Div Rheumatol, Sch Med, Baltimore, MD USA

[8] Univ Manchester, Salford Royal NHS Fdn Trust, Dermatol Ctr, Manchester NIHR Biomed Res Ctr, Manchester, England

[9] UCB Pharma, Slough, Berks, England

[10] UCB Pharma, Morrisville, NY USA

[11] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA

来源：

关键词：

Clinical trials; Psoriatic arthritis;

D O I：

10.1136/annrheumdis-2023-eular.1671

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

AB1099

引用

页码：1775 / 1776

页数：2

共 32 条